-+ 0.00%
-+ 0.00%
-+ 0.00%

Morgan Stanley Maintains Overweight on Legend Biotech, Raises Price Target to $49

Benzinga·08/12/2026 15:51:36
Listen to the news
Morgan Stanley analyst Matthew Harrison maintains Legend Biotech (NASDAQ:LEGN) with a Overweight and raises the price target from $48 to $49.